Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
Zepbound helps shed more weight than Wegovy, Eli Lilly study says
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...
Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
FierceBiotech4d
Novo Nordisk taps Photys for $186M cardiometabolic collab
With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...
FiercePharma4d
After studies flag possible link between Novo's Ozempic and rare eye disorder, Danish agency calls for probe
It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...
Novo Nordisk’s Hiring Binge Leaves Danish Firms Starved of Labor
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...